Considerations for cancer immunotherapy during the COVID-19 pandemic

Yada Kanjanapan*, Desmond Yip

*Corresponding author for this work

Research output: Contribution to journalComment/debatepeer-review

3 Citations (Scopus)

Abstract

Cancer immunotherapy during the COVID-19 pandemic presents management challenges related to immune-related toxicities, requiring careful patient selection.
Original languageEnglish
Pages (from-to)390-392.e1
JournalMedical Journal of Australia
Volume213
Issue number9
DOIs
Publication statusPublished - 1 Nov 2020

Fingerprint

Dive into the research topics of 'Considerations for cancer immunotherapy during the COVID-19 pandemic'. Together they form a unique fingerprint.

Cite this